MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Stoke Therapeutics Operating Expenses 2011-2026 | STOK
Annual Operating Expenses Stoke Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124 M | 117 M | 86.1 M | 53 M | 35.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 35.7 M | 83 M |
Quarterly Operating Expenses Stoke Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.7 M | 41.1 M | 47.3 M | - | 34.9 M | 34.2 M | 32.6 M | - | 30.5 M | 30.8 M | 29.8 M | - | 30.1 M | 28.5 M | 27.8 M | - | 22.7 M | 22 M | 16.8 M | 14.6 M | 13.7 M | 13 M | 11.7 M | 11.1 M | 9.84 M | 8.44 M | 6.32 M | 4.54 M | 3.32 M | 3.01 M | 1.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53.7 M | 1.91 M | 21.6 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.7 | -1.24 % | $ 2.61 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.84 | 7.59 % | $ 4.58 M | China |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 166.38 | 1.52 % | $ 8.28 B | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.82 | 5.82 % | $ 1.14 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.73 | 3.44 % | $ 1.37 B | Britain |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 26.86 | -3.83 % | $ 719 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.02 | 0.99 % | $ 74.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Cellectis S.A.
CLLS
|
109 M | $ 3.8 | -2.06 % | $ 116 M |  France |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
CNS Pharmaceuticals
CNSP
|
14.9 M | $ 3.13 | -0.95 % | $ 1.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Collegium Pharmaceutical
COLL
|
67.6 M | $ 41.6 | -0.17 % | $ 1.32 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 35.97 | 0.76 % | $ 3.74 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 23.88 | 3.47 % | $ 2.92 B | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
45.1 M | $ 8.35 | -2.57 % | $ 36.1 M | USA |
 |
Curis
CRIS
|
33.9 M | $ 1.08 | -5.26 % | $ 6.81 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
173 M | $ 40.68 | -1.02 % | $ 3.83 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
23.4 M | $ 17.89 | -2.03 % | $ 859 M | USA |
 |
Champions Oncology
CSBR
|
12.5 M | $ 6.07 | 2.71 % | $ 82.9 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.72 | -2.3 % | $ 4.84 M | USA |
 |
CEL-SCI Corporation
CVM
|
26.4 M | $ 3.83 | -10.09 % | $ 244 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Daré Bioscience
DARE
|
23.5 M | $ 1.61 | -5.29 % | $ 13.7 M | USA |
 |
DBV Technologies S.A.
DBVT
|
121 M | $ 23.25 | 10.77 % | $ 2.26 B | France |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Precision BioSciences
DTIL
|
92.5 M | $ 4.33 | 3.1 % | $ 16.6 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
46 M | $ 3.34 | 0.3 % | $ 1.2 M | USA |
 |
Dyadic International
DYAI
|
10.1 M | $ 0.77 | -1.68 % | $ 22.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Editas Medicine
EDIT
|
283 M | $ 2.15 | -2.27 % | $ 177 M | USA |
 |
Edesa Biotech
EDSA
|
6.71 M | $ 2.28 | 3.64 % | $ 7.29 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
543 M | $ 29.2 | -3.41 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Equillium
EQ
|
50.6 M | $ 1.92 | 5.49 % | $ 66.7 M | USA |